Membrane Binding of Parkinson's Protein alpha-Synuclein: Effect of Phosphorylation at Positions 87 and 129 by the S to D Mutation Approach by Kumar, P. et al.
DOI: 10.1002/ijch.201600083
Membrane Binding of ParkinsonQs Protein a-Synuclein:
Effect of Phosphorylation at Positions 87 and 129 by the S
to D Mutation Approach
Pravin Kumar,[a] Nathalie Schilderink,[b] Vinod Subramaniam,[b, c, d] and Martina Huber*[a]
1. Introduction
ParkinsonQs disease[1] is the second-most prevalent neuro-
degenerative disease after AlzheimerQs disease.[2] This dis-
ease is characterized by the formation of protein deposits,
such as Lewy bodies, in the brain.[3,4] The protein a-synu-
clein (aS) constitutes the main component of these de-
posits.[5–7] A number of posttranslational modifications of
aS are present within the Lewy bodies in ParkinsonQs dis-
ease (PD) and related disorders.[8,9] The major disease-as-
sociated posttranslational modifications are phosphoryla-
tion,[8,10] truncation, ubiquitination,[11] and also oxidation
(like nitration),[12] but one of the key posttranslational
modifications is phosphorylation. The protein aS has
been found hyperphosphorylated in Lewy bodies and
Lewy neurites.[1,9,13] The role of phosphorylation of aS in
neurotoxicity is controversial. However, growing evidence
suggests that phosphorylation could influence membrane/
vesicle binding of aS and its aggregation.[8,14–17] Recent re-
views summarize results of in vivo and in vitro studies
performed up to now and describe to which degree phos-
phorylation of aS is linked to disease.[18,19] The major
phosphorylation sites of aS are shown in Figure 1. The
phosphorylation sites Y125, S129, Y133, and Y136 are the
most discussed in the literature; for example, S129 is
highly phosphorylated in Lewy bodies. One more phos-
phorylation site, S87, is special, since it distinguishes the
human aS sequence from that of mouse and rat. Also,
a link between phosphorylation at 87 and disease was dis-
cussed by Paleologou et al.[13]
Here, we focus on the membrane-binding aspect of aS
phosphorylation in vitro at positions S87 and S129. Mem-
brane binding of aS concerns an amphipathic helix span-
Abstract : Human a-synuclein, a protein relevant in the brain
with so-far unknown function, plays an important role in
Parkinson’s disease. The phosphorylation state of aS was
related to the disease, prompting interest in this process.
The presumed physiological function and the disease action
of aS involves membrane interaction. Here, we study the
effect of phosphorylation at positions 87 and 129, mimicked
by the mutations S87A, S129A (nonphosphorylated) and
S87D, S129D (phosphorylated) on membrane binding. Local
binding is detected by spin-label continuous-wave electron
paramagnetic resonance. For S87A/D, six positions (27, 56,
63, 69, 76, and 90) are probed; and for S129A/D, three (27,
56, and 69). Binding to large unilamellar vesicles of 100 nm
diameter of 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1’-rac-
glycerol) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocho-
line in a 1 : 1 composition is not affected by the phosphory-
lation state of S129. For phosphorylation at S87, local un-
binding of aS from the membrane is observed. We specu-
late that modulating the local membrane affinity by phos-
phorylation could tune the way aS interacts with different
membranes; for example, tuning its membrane fusion activ-
ity.
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ning residues 1–100.[20–22] The N-terminal half (residues 1–
50) of the amphipathic helix is termed helix 1, and the
other half (residues 51–100), helix 2. The affinity of aS to
membranes depends on the negative charge density (1) of
the membrane, where 1 represents the molar fraction of
anionic lipids present in the membrane.[23] Different bind-
ing properties were found for helix 1 and helix 2.[24]
There are three ways to generate protein constructs to
study the effect of phosphorylation: 1) to phosphorylate
the respective residues enzymatically, which requires
dedicated enzymes/overexpression systems[25,26] and is re-
versible; 2) by a semisynthetic approach, in which a (phos-
phorylated) peptide is linked to the corresponding over-
expressed protein;[27] and 3) by generating mutants whose
side chains mimic the chemical properties of the phos-
phorylated state (negative charge) and size, sometimes re-
ferred to as pseudophosphorylation.[28] Typically, S is re-
placed by D or E[13,17,29,30] to mimic phosphorylation, and
alanine is used as the reference for the nonphosphorylat-
ed state, especially for in vivo studies.
All three approaches have been used to study aS phos-
phorylation in vivo and in vitro, showing that in some
cases, enzymatically phosphorylated aS (P-aS) and pseu-
dophosphorylated aS can behave differently.[29,31] For ex-
ample, enzymatic phosphorylation of aS at S129 has been
shown to have an inhibitory effect on aS aggregation,
while pseudophosphorylation does not show such an
effect.[29] Apparently, the different behavior depends
strongly on the properties probed and the environment
aS is exposed to. In the present study, we focus on the
phosphomimic approach with the S!D substitution to
mimic phosphorylation, and investigate the constructs
S87A or S129A (nonphosporylated); and S87D or S129D
(phosphorylated).
We used large unilamellar vesicles (LUVs) as mem-
brane models with a 1 : 1 mixture of the lipids 1-palmi-
toyl-2-oleoyl-sn-glycero-3-phospho-(1’-rac-glycerol)
(POPG) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-
choline (POPC), generating a membrane with a charge
density 1=0.5. Previous studies on model membranes
showed that at high charge densities, i.e., above 0.8–0.9,
aS is fully bound to those membranes,[23,24,32–34] revealing
that the interaction is strong and dominated by electro-
statics, which risks masking the effects of phosphoryla-
tion. Additionally, such charge densities are nonphysio-
logical, so we avoided these high negative charge densi-
ties. At low charge densities (1,0.2), i.e. , on neutral or
weakly negatively charged membranes, binding is very
low, resulting in a large fraction of unbound protein,
which would also abolish any differential binding effect
of phosphorylation. This made 1=0.5 an optimum charge
density at which to work.
To investigate membrane binding, we used spin-label
electron paramagnetic resonance (EPR) spectroscopy.
For spin labelling, the amino-acid residue at the sequence
position of interest is replaced by a cysteine, which is re-
acted with a suitable functional group of the nitroxide
spin label (see Figure 1b), an approach introduced by the
Hubbell group.[35a] In this way, a nitroxide, which contains
an unpaired electron and is therefore EPR active, is cova-
lently attached to the protein. Then the properties of the
protein can be probed at the modified position by EPR.
In the present study, we make use of the ability of EPR
to detect the mobility of the spin label by room-tempera-
ture continuous-wave (cw) EPR. Characteristic line
shapes of the spectra reveal the mobility of the spin label,
with narrow lines corresponding to fast motion (i.e., rota-
tional correlation times (tr) of several hundreds of ps)
and broad lines to slow motion, in the ns-regime. In our
particular case, slow motion of the spin label shows that
the section of the protein to which the spin label is at-
tached is bound to the membrane, whereas fast motion
shows detachment of the protein from the membrane.
The methodology described was introduced before and
has proven valuable for determining the local binding of
aS to membranes.[24,32–34]
The spin-labelled constructs are referred to as SLposi-
tionaS/S87A(D) or SLpositionaS/S129A(D), such that,
for example, SL27aS/S87D is the construct with the spin
label at position 27 and is the phosphorylated variant at
position 87. We investigated several spin-label positions
for each phosphorylation site, resulting in a total of nine
constructs, as summarized in Table 1.
In this work, we show how phosphorylation affects the
binding of aS to the membrane. It decreases the binding
of aS to the membrane when phosphorylated at the S87
position, whereas no effect is seen when phosphorylated
Figure 1. a) The most common phosphorylation sites in aS. Given
is the sequence number (in boldface), preceded by the residue (Y
or S) that is phosphorylated. Also, the important regions of the
protein are shown, indicated by sequence numbers at the start
and end. Positively charged (green): net positive charge of protein
between residues 1 and 61; NAC (blue): non-amyloid-b component;
and negatively charged C-terminal part of the protein (red), from
residue 95 onwards. b) Chemical structure of the spin-label MTSL,
by which cys is labelled.
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at the S129 position. We also show that phosphorylation
at position 87 does not detach the protein completely
from the membrane, but rather, causes local unbinding,
which is particularly pronounced in the helix 2 region.
2. Results and Discussion
2.1. Results
We investigate the binding of phosphorylation variants of
aS at positions 87 and 129 to LUVs of 100 nm diameter.
The LUVs are composed of a 1 :1 mixture of POPG and
POPC, generating a membrane of charge density 1=0.5.
We first describe the results of phosphorylation at posi-
tion 87, then at 129.
Figure 2 shows the spectra of the spin-labelled con-
structs probing phosphorylation at position 87 in the pres-
ence of LUVs (for the complete list of constructs, see
Table 1). In this set, helix 1 is probed in the middle, at
residue 27; helix 2 is probed at five probing positions,
starting from position 56 and terminating at 90. Figure 2a
shows the spectra of aS in the nonphosphorylated form
and Figure 2b in the phosphorylated form. The spectra in
Figure 2a differ from those in Figure 2b; most notably,
each spectrum in Figure 2b has narrower lines than its
counterpart in Figure 2a. As described in the introduc-
tion, narrow lines derive from spin labels that are rotating
fast. As discussed in more detail below, fast rotation
shows that the section of the protein to which the spin
label is attached is not bound to the membrane. More de-
tailed information was obtained by spectral simulation of
the experimental spectra, which yields the parameters of
mobility of the spin label, the rotational correlation
time (tr), and in the case of multicomponent spectra, the
amount by which each fraction contributes. These param-
eters are given in Table 2. In Figure 2c, an example of
a simulation is shown. Three fractions are visible: the
fast, the slow, and the immobile components, which have
increasingly large linewidths. The individual components
add up to give the experimental spectrum. Table 2 reveals
that all but two spectra consist of a superposition of two
components, the fast and slow components, except for the
SL56aS/S87A variant, which, in addition, has a third, the
immobile component, and the SL90aS/S87A and SL90aS/
S87D variants, which have only one component, the fast
component. Each component reflects a part of the pro-
tein population: the fast fraction is due to protein in
which the region around the site that is spin labelled is
not attached to the membrane, whereas the slow and im-
mobilized fractions are due to the sections bound to the
membrane. The amount by which each component con-
tributes to the spectra (Table 2, columns four and six) re-
flects the fraction of protein contributing to each compo-
nent. The correlation times can be determined to several
tens of ps in the case of the fast fraction, and several hun-
dred ps for the slow fraction (see Table 2). The contribu-
tion of the fast component of aS in the nonphosphorylat-
ed form is smaller than in the phosphorylated form for
each probing position. The opposite is the case for the
contribution of the slow components. Both these trends
reveal that phosphorylation reduces membrane binding.
To illustrate the effect of phosphorylation at position 87,
Figure 3 shows a plot of the amount of the fast fraction
for phosphorylation at position 87 as a function of the se-
quence number at which mobility is probed.
For all monitoring positions, the amount of the mobile
fraction is larger in the phosphorylated variant. At moni-
toring positions 27 and 56, the amount of mobile fractions
of nonphosphorylated aS is below 10 %, which indicates
strong binding, but at later positions (helix 2), the
amount of fast fractions increases to 70 %, indicating the
loosening of the helix 2 of aS when it is nonphosphorylat-
ed, in agreement with previous findings for wt aS.[24] For
the phosphorylated aS, the amount of the mobile fraction
is higher than in the nonphosphorylated form for all posi-
tions monitored, enhancing the tendency for local unbind-
ing in helix 2, until, at position 90, the bound fraction is
so low that it becomes undetectable.
To determine if the phosphorylation reduces the overall
membrane affinity of aS, i.e., if aS detaches completely
from the membrane, resulting in aS protein that is free in
solution (physical unbinding), we separated the physically
Table 1. The aS constructs used to study phosphorylation at position S87 and S129; SL denotes the position of the spin label.
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unbound fraction of aS from the membrane-bound frac-
tion, by filtrating the sample through a filter that retains
the vesicles and aS bound to them. The amount of physi-
cally unbound protein in the filtrate is then determined
by EPR, as described in Drescher et al.[24] (for details, see
Section 4). The amount of unbound aS is given in
Table 3, and is below 16 % for all constructs. Thus, the
amount of physically unbound aS is significantly lower
than the amount of the fast fraction measured by EPR
(see Table 2), showing that the local unbinding far out-
weighs any physical unbinding. The percentages in
Table 3 for spin-label positions 27 and 56 are slightly
lower than for the other positions. Given that the differ-
ences are just outside the error margins of the procedure,
we cannot draw conclusions.
For phosphorylation at position 129, Figure 4 shows the
superposition of the spectra of nonphosphorylated and
phosphorylated variants for three spin-label positions (see
Table 1). In contrast to phosphorylation at position 87, A
and D variants at position 129 have similar spectra, obvi-
ating the need for detailed spectral analysis. Apparently,
phosphorylation has a much smaller influence at position
129 than at position 87.
2.2. Discussion
We have investigated how the membrane binding of aS
depends on the phosphorylation state of positions 87 and
129. Membrane binding is detected locally, via the mobili-
ty of spin labels attached to specific positions in the pro-
tein. An increased spin-label mobility shows that the pro-
tein detaches from the membrane around the position
probed.
The membrane composition was chosen to be condu-
cive to intermediate binding, with a charge density of
1=0.5, to avoid dominant electrostatic effects, which are
observed at higher charge densities, where they cause
strong, undifferentiated binding and are nonphysiological,
or low charge densities, causing overall unbind-
ing,[23,24,32–34] as described in the Introduction. The mem-
brane was offered in the form of LUVs of a diameter of
100 nm. We mimic phosphorylation by the phosphoryla-
tion-mutation approach, replacing S by D, an approach
used before[13,17,29,30] (for details, see Introduction). Al-
though some studies showed that biochemically phos-
phorylated aS can have different properties than phos-
phorylation mimics,[29,31] the latter constructs provide
a robust system to study phosphorylation effects in vitro,
explaining their popularity.
Under the conditions of our study, phosphorylation at
position 129 has no noticeable effect on membrane bind-
ing, whereas 87 has, similar to what was observed by
other techniques in the past.[13] In the following, we will
first discuss the influence of phosphorylation at position
87 on aS membrane binding, and then compare the re-
Figure 2. Effect of phosphorylation at position 87 on aS binding
to LUVs: room-temperature EPR spectra of spin-labelled aS con-
structs (for nomenclature see Table 1) with LUVs of a 1 : 1 mixture
of POPG and POPC: a) nonphosphorylated; and b) phosphorylated
forms. Black line: experiment; red line: simulation. c) Decomposi-
tion of EPR spectrum into components shown for SL56aS/S87A.
The fast (black), slow (red), and immobilized (blue) components
are shown, as well as the added simulation (green) and the experi-
mental spectrum (pink).
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sults obtained on both phosphorylation sites to previous
findings in the literature.
When position 87 is phosphorylated, membrane bind-
ing is reduced relative to the nonphosphorylated case. An
almost constant reduction of the binding is observed at
positions 27 and 56 in the helix 1 region: see Figure 3.
Similar to wild-type aS,[24] also in the S87A variants,
helix 2 has a lower membrane affinity than helix 1. Phos-
phorylation enhances this trend, up to the point that at
probing position 90, the bound fraction becomes so low
that is undetectable within experimental error. Complete
physical detachment of the phosphorylated protein from
the membrane does not play a role: as seen in Table 3,
the physically unbound fraction is below 16% for all con-
structs. To place this into perspective, the amount of phys-
ically unbound aS is maximally one-third of the amount
of fast fraction determined from EPR, showing that the
majority of the fraction, seen by EPR, derives from pro-
tein that is attached to the membrane, presumably at the
residues preceding the probed sequence position, e.g., for
sample SL27/aS87P, residues 27 and below. Fluctuations
in the amount of fast fraction (Table 2, SL 63, nonphos-
phorylated (SL63/S87A) has a larger amount of fast frac-
tion than SL 69), and a larger amount of physically un-
bound aS for SL positions in helix 2 (Table 3), could indi-
cate an influence of the spin label on aS membrane bind-
ing. If such an effect is present, it never exceeds a contri-
bution of 10 %, and therefore is not relevant for the
conclusions drawn.
Overall, we find that phosphorylation at position 87 de-
creases the membrane affinity of aS, particularly for
helix 2. This effect is fully consistent with the change in
the charge caused by the conversion of S!D or by phos-
phorylation: A negative charge in the helix 2 will weaken
the electrostatic interaction with the negatively charged
Table 2. Effect of phosphorylation of aS at position 87 (S87A/D): parameters describing the mobility of the spin label in the EPR spectra; tr
is the rotation correlation time of the spin label.
aS spin-label positions Components contributing to spectra S87A (nonphosphorylated) S87D (phosphorylated)
tr (ns) Contribution (%) tr (ns) Contribution (%)
SL 27 fast 0.4:0.03 6:0.4 0.4:0.02 32:2
slow 8.5:0.2 94:0.4 9.3:0.65 67:2
immobile na na na na
SL 56 fast 0.4:0.02 6:0.2 0.4:0.03 34:3
slow 3.2:0.07 78:1.2 3.1:0.4 63:3
immobile >50 16:1 na na
SL 63 fast 0.35:0.04 29:2 0.4:0.03 51:5
slow 2.6:0.3 70:2 2.5:0.6 44:5
immobile na na na na
SL 69 fast 0.3:0.02 23:2 0.3:0.02 75:9
slow 2.5:0.2 75:2 2.5:1.2 20:9
immobile na na na na
SL 76 fast 0.4:0.04 42:5 0.4:0.02 79:8
slow 3.5:0.8 57:5 3.5:3.2 16:8
immobile na na na na
SL 90 fast 0.4:0.04 70:10 0.3:0.03 100[a]:8
slow 2.5:1.3 24:10 na na
immobile na na na na
na: a component seen in other spectra, but not required to obtain a good simulation of the experimental spectrum in question, revealing
that the rotational correlation time of the spin label does not contain contributions on the timescale of the component in question (for de-
tails, see text and Figure 2). For error determination, see Section 4. [a] including 4.5 % contribution of spin label with natural abundance of
13C.
Figure 3. Local-unbinding effect of phosphorylation at position 87:
amount of fast fraction in aS 87 A,D mutants in the presence of
LUVs as a function of the sequence number. Black: nonphosphory-
lated (aS87A); red: phosphorylated (aS87D) (see Table 2 for
values); the lines connecting the points are guides for the eye.
Table 3. Physical unbinding of aS S87D from the membrane: re-
sults of filtration experiments (for details, see Sections 4 and 2.1).
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membrane surface, as it counteracts the effect of several
lysines (Lys; K) in the aS sequence from residues 1–100.
Reduced membrane binding of S87E and P-S87 has been
reported before, e.g., Refs. [13] and [35b].
Reduced membrane binding affects the entire protein,
but is most pronounced in the helix 2 region, and may se-
lectively influence the behavior of helix 2. Some models
propose that the physiological function of aS involves
vesicle fusion events in which helix 1 and helix 2 interact
with different types of membranes.[36] We therefore specu-
late that phosphorylation at position 87 could be used to
tune how aS operates in vesicle trafficking.
For the aS129 A/D variants, the difference in mobility
of the spin label for phosphorylated and nonphosphory-
lated forms is minute, showing that under the membrane
conditions employed here, phosphorylation at this site
does not affect membrane binding. The C-terminus of aS
is already negatively charged and was not found to inter-
act with the membrane in previous studies,[20,21,24,37,38]
which is fully consistent with the lack of changes in mem-
brane binding observed in the present study upon phos-
phorylation at position 129.
The results of the present study suggest that phosphor-
ylation at position 87 tunes those functions of aS that in-
volve membrane binding and vesicle interaction, whereas
phosphorylation at position 129 acts on other aspects of
aS in the organism. Previously,[13] several possibilities of
how phosphorylation at 129 could affect aS in vivo be-
havior have been described and the study of Kosten
et al.[39] shows that the phosphorylation at position 129 de-
pends on the phosphorylation state of position 125, sug-
gesting a complex interplay of posttranslational modifica-
tions in the C-terminus.
Most of the current research is focused on phosphory-
lation at position 129, and the phosphorylation degree at
this position is related to disease effects, as reviewed in
Ref. [40]. In agreement with our results, several studies
show that aS phosphorylation at 129 has no or little
effect on membrane binding; see, for example, Ref. [28];
however, several studies find an influence of phosphoryla-
tion at 129 on the aggregation of aS[28,29,41] and on mem-
brane binding of aS aggregates,[41] suggesting that in vivo
effects are linked to aggregation-sensitive processes.
3. Conclusion
In conclusion, the large spectrum of phosphorylation ef-
fects on aS in vivo and in vitro[13,14,16,19,28–31,35b,40–50] fur-
nishes the need for isolating the different factors that can
be modulated by aS phosphorylation in vitro. The present
study gives one such example, where we show that in
vitro phosphorylation mimics at position 87 (S87D)
reduce aS membrane binding in a local, sequence-depen-
dent manner, whereas the same modification at position
129 (S129D) has no influence on membrane binding. We
expect that this approach provides a foothold to inter-
preting the challenging in vivo physiological and patho-
logical functions of aS.
4. Materials and Methods
4.1. Protein Expression and Labelling
All aS mutants were expressed in Escherichia coli strain
BL21(DE3) using the pT7-7 expression plasmid and puri-
Figure 4. Effect of phosphorylation at position 129 on aS binding
to LUVs: room-temperature EPR spectra of spin-labelled aS con-
structs (for nomenclature, see Table 1) with LUVs of a 1 : 1 mixture
of POPG and POPC; superposition of nonphosphorylated (black
line) with phosphorylated EPR spectra (red line), normalized by
their double-integral value.
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fied in the presence of 1 mM DTT, as previously report-
ed[51,52] Serine-87 is substituted either by Alanine (S87A,
represents phosphorylation- inactive form) or by Aspar-
tate (S87D, represents phosphomimic form). For label-
ling, a cysteine mutation was introduced at the desired
residues.
Spin labelling was done following the standard proto-
col, described briefly. Before starting labelling, aS cys-
teine mutants were reduced with a six-fold molar excess
per cysteine with DTT (1,4-dithio-D-threitol) for 30 min
at room temperature. To remove DTT, samples were
passed through a Pierce Zeba 5 ml desalting column. Im-
mediately, a ten-fold molar excess of the MTSL spin label
((1-oxyl-2,2,5,5-tetramethylpyrroline-3-methyl)-methane-
thiosulfonate) was added (from a 25 mM stock in
DMSO) and incubated for 1 h in the dark at room tem-
perature. After this, the free spin label was removed by
using two additional desalting steps. Protein samples were
applied onto Microcon YM-100 spin columns to remove
any precipitated and/or oligomerised proteins and were
diluted in buffer (10 mM Tris-HCl, pH 7.4). Spin-label
concentrations were 2.5 mM at protein concentrations of
250 mM. Owing to the high reactivity of the label and the
fact that the cysteine residues were freely accessible in
the poorly folded structure, near quantitative labelling
could be achieved under these conditions.[37] Samples
were stored at @80 8C.
4.2. Preparation of Vesicles
All lipids were purchased from Avanti Polar Lipids, Inc.
as chloroform solutions and were used without further
purification. LUVs were prepared from 1 :1 mixtures of
1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1’-rac-glycer-
ol) (POPG) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phos-
phocholine (POPC). Lipids were mixed in the desired
ratio and then chloroform was evaporated by dry nitro-
gen gas. The resulting lipid films were kept under vacuum
overnight. Dried lipid films were hydrated with 10 mM
Tris-HCl, pH 7.4 for 1 hour at 30 8C, and the resulting
milky lipid suspensions were extruded through 100 nm
pore size polycarbonated membranes using the mini ex-
truder (catalogue no. 610000) from Avanti Polar Lipids.
The size of the vesicles was determined by dynamic light
scattering (DLS). The DLS-experiments were performed
on a Zetasizer Nano-ZS (Malvern). We obtained vesicles
with a homogeneous size distribution around d=100 nm.
4.3. Sample Preparation
Spin-labelled aS mutants were added from stock solu-
tions (concentration between 150 mM and 250 mM) to the
LUVs to obtain a lipid to protein ratio (L : P) of 250 : 1,
and incubated for 30 min at room temperature before
measuring. All samples were prepared and measured at
least three times. All spin-labelled aS constructs used in
this work are shown in the Table 1.
4.4. Filtration Experiments
To determine, if aS physically detaches from the mem-
brane, we performed filtration experiments similar to
those described in Drescher et al.[24] An aS vesicle solu-
tion, prepared as for the EPR experiments described
above (sample preparation), was passed through
a 100 kDa cutoff filter device (Amicon Ultra 100k) which
retained the vesicles, and thereby, the membrane-bound
aS fraction, but was permeable for unbound aS. The con-
centration of aS in the filtrate was too low to measure di-
rectly; therefore, the filtrate was concentrated using
a 3 kDa cutoff filter device (Amicon Ultra 3k) and mea-
sured by EPR to determine the amount of aS in the fil-
trate. The error in the final value, of the order of 20 %, is
largely due to the errors in determining the volumes
before and after the concentration step, and the error of
the double-integral procedure to determine the spin con-
centration by EPR.
4.5. Continuous-wave EPR Experiments
The X-band continuous-wave EPR measurements were
performed using an ELEXSYS E680 spectrometer
(Bruker, Rheinstetten, Germany) with a super high Q
cavity (ER 4122 SHQE-W1/1108). Measurements were
performed at 20 8C, using 0.63 mW of microwave power,
100 kHz modulation frequency, and a modulation ampli-
tude of 1.0 G. Total acquisition time for the EPR spectra
was 20 minutes.
4.6. Simulation of cw-EPR Spectra
Spectral simulations were performed using Matlab
(7.11.0.584, Natick, Massachusetts, U.S.A.) and the Easy-
Spin package.[53] For all simulations, the following spectral
parameters were used: g= [2.00906, 2.00687, 2.00300][54]
and the hyperfine tensor parameters AXX=AYY=13 MHz.
Usually, a superposition of more than one component
was required to simulate the spectra. The parameters
were manually changed to check in which range accepta-
ble simulations of the experimental spectra were obtained
to determine the error margins. To simulate spectra of aS
bound to membranes, the tr of the fastest component was
kept at the tr value of the spectra of the respective pro-
tein construct, in the absence of vesicles.
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